Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials-Reference-Cited by-同舟云学术

Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials

Published:2023-02-20 Issue:3 Volume:24 Page:469-483
ISSN:1175-0561
Container-title:American Journal of Clinical Dermatology
language:en
Short-container-title:Am J Clin Dermatol

Author:

Silverberg Jonathan I.^ORCID,Lynde Charles W.,Abuabara Katrina^ORCID,Patruno Cataldo^ORCID,de Benedetto Anna^ORCID,Zhang Haixin,Thomas Ryan B.,Bégo-Le-Bagousse Gaëlle,Khokhar Faisal A.,Vakil Jignesh,Marco Ainara Rodríguez,Levit Noah A.^ORCID

Funder

Sanofi and Regeneron Pharmaceuticals, Inc.

Publisher

Springer Science and Business Media LLC

Subject

Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40257-022-00754-4.pdf

Reference36 articles.

1. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132(5):1132–8.

2. Chan LN, Magyari A, Ye M, Al-Alusi NA, Langan SM, Margolis D, et al. The epidemiology of atopic dermatitis in older adults: a population-based study in the United Kingdom. PLoS ONE. 2021;16(10): e0258219.

3. De Lusignan S, Alexander H, Broderick C, Dennis J, McGovern A, Feeney C, et al. The epidemiology of eczema in children and adults in England: a population-based study using primary care data. Clin Exp Allergy. 2021;51:471–82.